Labcorp Holdings Inc.
LHLabcorp Holdings Inc. (LH) is a leading global life sciences company providing diagnostic, testing, and clinical trial services. Founded in 1978, it offers a broad range of laboratory testing, drug development, and one-health solutions to healthcare providers, pharmaceutical companies, and biopharmaceutical firms. Headquartered in Burlington, North Carolina, Labcorp plays a key role in advancing personalized medicine and improving patient outcomes through its extensive diagnostic and research capabilities.
Dividend History
Investors can expect a dividend payout of $0.72 per share, scheduled to be distributed in 55 days on September 11, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 11, 2026 | $0.72 | 2026-08-28 | 2026-08-28 |
| June 11, 2026 | $0.72 | 2026-05-29 | 2026-05-29 |
| March 12, 2026 | $0.72 | 2026-02-27 | 2026-02-27 |
| December 11, 2025 | $0.72 | 2025-11-26 | 2025-11-26 |
| September 11, 2025 | $0.72 | 2025-08-28 | 2025-08-28 |
Dividends Summary
- Consistent Payer: Labcorp Holdings Inc. has rewarded shareholders with 18 dividend payments over the past 4 years.
- Total Returned Value: Investors who held LH shares during this period received a total of $12.96 per share in dividend income.
- Latest Payout: The most recent dividend of $0.72/share was paid 37 days ago, on June 11, 2026.
- Yield & Schedule: LH currently pays dividends quarterly with an annual yield of 1.02%.
- Dividend Growth: Since 2022, the dividend payout has grown by 0.0%, from $0.72 to $0.72.
- Dividend Reliability: LH has maintained or increased its dividend for 18 consecutive payments.
Company News
Onconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. H...
Labcorp Holdings (LH) shares rose 1.46% after reporting strong Q1 results with adjusted EPS of $4.25 beating consensus of $4.09, and sales of $3.54 billion exceeding expectations. The company raised full-year 2026 adjusted EPS guidance to $18.03 at midpoint, driven by momentum in Diagnostics and Central Laboratory businesses, along with investmen...
The drug development services market is projected to grow from $28.09 billion in 2025 to $50.26 billion by 2030 at a CAGR of 12.4%, driven by increased R&D investments, AI adoption, personalized medicine, and emerging market expansion. Key growth areas include preclinical research, regulatory optimization, and cloud-based data management, with pr...
Labcorp Holdings Inc. (NYSE:LH) announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record as of May 29, 2026.
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fu...
